IQVIA

Market Reflection Report

Jan 2024

9th February

© 2024. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
 IPM Overview
TSA SSA
Growth %%

80 60
60 2021-22 2021-22
40
40 2022-23 2022-23
20
20 2023-24
0 2023-24
0
-20 -20
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan

TSA IPM Trends (Value Rs. 214,476 Crs) – MAT Jan’24 SSA IPM Trends (Value Rs. 181,238 Crs) – MAT Jan’24

7.9%
10.1% 8.0%
9.9%
MAT
214,476 MAT
Month 181,238
194,761 Month
184,825 164,879
156,827

154,787
132,643

13,181 15,979 16,618 17,937 13,676 14,052 15,171

11,123

2021 2022 2023 2024 2021 2022 2023 2024

• TSA valued at Rs. 214,476 Cr with growth of 10.1% as of MAT Jan'24 and Rs 17,937 Cr for Jan'24 month with growth of 7.9%
• SSA valued at Rs. 181,238 Cr with growth of 9.9% as of MAT Jan'24 and Rs 15,171 Cr for Jan'24 month with growth of 8.0%

IQVIA TSA & SSA Dataset Jan'24 1

 Amongst top 10 contributing therapies, Cardiac followed by Anti-
Diab and Pain posted highest growth
TSA

MOM Trend Gwth % (SPLY)

Value (Rs. Crs)
24 20 17
IPM 17,937 12 10 5 7 6 9 4 5 8
IPM
17 13 12 14 12
9 9 11 9 8 8
Cardiac 2,377 5 Cardiac
52 51
26 9 12 24
-1 -5 -2 4 1 2 AI
AI 1,918
24 15 18
Gastro 1,818 7 6 4 7 8 11 5 6 9
Gastro
56 50
30 16
Respi 1,716 10 -5 -4 9 3 -2 1 Respi
-6
13 9 10
8 6 6 9
Anti Diab 1,637 5 4 4 5 ADB
26 2
22 15 12 10 17 9
6 7 5 3 5 Pain
Pain 1,359
17 19
12 9 8 7 8
7 5 7 2 5
VMN 1,306 VMN
12 11
7 6 8 8 6 8 5 7
3 Derma
Derma 1,222 -2
16 11 12 15
9 7 9 7 8 6 6 8
Neuro 1,099 Neuro
17 15
10 8 4 10 8 5 5 7
4 1
Gynaec. 867 Gynaec
28 29 27 16 18 27 23 24 29 30 23 24
Antineoplast 457 16 Antineoplast
19 18 18 8 15 Urology
13 12 11
13 16 15
Urology 395
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan

IQVIA TSA & SSA Dataset Jan'24 2

Therapy sorted on Month
 Top Companies #1-10 Market Share Trend
9

Val Jan’24 MS Jan’24

8 SUN* 1423 7.93

ABBOTT* 1110 6.19

(CIPLA) 1043 5.82

7
(MANKIND) 798 4.45

(ALKEM*) 690 3.85

6
INTAS* 662 3.69
LUPIN 629 3.51
5
TORRENT 620 3.46
(MACLEODS) 593 3.30
4 (DRL) 518 2.89

2
Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23 Nov’23 Dec’23 Jan’24

• Sun*, Abbott*, Intas* & Torrent have shown improvement in MS for Jan’24 as compared to Dec’23
• Lupin maintained MS in the month of Jan’24
• Cipla, Mankind, Alkem*, Macleods & DRL reflected dip in MS for Jan’24 as compared to Dec'23

IQVIA TSA & SSA Dataset Jan’24 3

 Top Companies #1-10
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

SUN* 1,423 9 101 SUN* 1,208 8 100

ABBOTT* 1,110 10 102 ABBOTT* 957 12 104
CIPLA 1,043 10 102 CIPLA 899 12 103
MANKIND 798 9 101 MANKIND 726 10 102
Month

Month
ALKEM* 690 6 98 ALKEM* 606 8 100
INTAS* 662 14 105 TORRENT 553 10 102
LUPIN 629 7 99 LUPIN 544 8 100

TORRENT 620 9 101 INTAS* 536 12 104

MACLEODS 593 9 101 MACLEODS 526 8 100

8 100 DRL 453 10 102
DRL 518

SUN* 16,560 10 100 SUN* 14,061 9 99

ABBOTT* 13,294 10 100 ABBOTT* 11,399 11 101
CIPLA 11,597 11 101 CIPLA 9,842 12 102
MANKIND 9,465 12 102 MANKIND 8,559 12 102
MAT

101 101

MAT
ALKEM* 8,696 11 ALKEM* 7,577 11
INTAS* 7,566 13 103 TORRENT 6,440 10 100
LUPIN 7,317 7 97 MACLEODS 6,364 13 103
TORRENT 7,290 10 99 LUPIN 6,257 7 97
MACLEODS 7,180 13 103 INTAS* 6,144 12 102
ARISTO* 6,345 14 104 ARISTO* 5,743 14 104

• TSA and SSA : Intas* has posted highest growth for the month followed by Abbott* & Cipla, while on MAT level, Aristo* is the fastest growing company

IQVIA TSA & SSA Dataset Jan'24

4
 Top Companies #11-20 Market Share Trend
3.4

3.2
Val Jan’24 MS Jan’24
3.0
ZYDUS* 514 2.87
2.8
(ARISTO*) 481 2.68
2.6 (GSK*) 413 2.30
2.4 GLENMARK 406 2.26
2.2 USV 355 1.98

2.0 EMCURE* 354 1.97

(IPCA) 329 1.84
1.8
(SANOFI*) 295 1.65
1.6
(MICRO *) 275 1.54
1.4
(ALEMBIC) 272 1.51
1.2

1.0

0.8

0.6
Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23 Nov’23 Dec’23 Jan’24

• Zydus*, Glenmark, USV & Emcure* have shown improvement in MS for Jan’24 as compared to Dec’23
• Aristo*, GSK*, IPCA, Sanofi*, Micro* & Alembic reflected dip in MS for Jan’24 as compared to Dec'23
.

IQVIA TSA & SSA Dataset Jan’24 5

 Top Companies #11-20
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

6 98 ARISTO* 433 4 96
ZYDUS* 514
5 97 ZYDUS* 416 5 97
ARISTO* 481
1 93 GLENMARK 364 11 103
GSK* 413
10 101 GSK* 325 -3 90
GLENMARK 406
Month

Month
8 100 USV 321 10 102
USV 355
7 99 EMCURE* 292 5 97
EMCURE* 354
14 106 IPCA 283 14 106
IPCA 329
14 106 ALEMBIC 246 3 95
SANOFI* 295
0 92 MICRO * 236 0 92
MICRO * 275
2 95 SANOFI* 224 11 103
ALEMBIC 272

DRL 6,149 8 98 DRL 5,326 10 100

ZYDUS* 6,118 8 98 ZYDUS* 4,977 8 98
GSK* 5,172 5 95 GSK* 4,167 4 95
GLENMARK 4,371 11 101 GLENMARK 3,876 12 102
MAT

98 9 100

MAT
EMCURE* 4,287 8 USV 3,698
IPCA 4,187 14 103 IPCA 3,618 14 103
USV 4,130 9 99 EMCURE* 3,539 8 98
SANOFI* 3,484 8 98 MICRO * 2,946 6 96
MICRO * 3,436 5 95 ALEMBIC 2,873 10 100
PFIZER* 3,243 1 91 SANOFI* 2,619 4 95

• TSA : IPCA has posted highest growth for the month followed by Sanofi, while on MAT level, IPCA is the fastest growing company

• SSA : IPCA has posted highest growth followed by Glenmark for the month, while on MAT level, IPCA is the fastest growing company

IQVIA TSA & SSA Dataset Jan'24

6
 Top Companies #21-30 Market Share Trend
1.7
Val Jan’24 MS Jan’24
1.6 271 1.51
PFIZER*
1.5 (JB PHARMA*) 209 1.16

ERIS* 197 1.10

1.4
FDC 184 1.02
1.3
AJANTA 140 0.78
1.2 (HIMALAYA ) 133 0.74

1.1 LA RENON 126 0.70

CADILA 125 0.70

1.0
CORONA 109 0.61
0.9 109 0.61
INDOCO*
0.8

0.7

0.6

0.5
Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23 Nov’23 Dec’23 Jan’24

• Pfizer*, Eris*, FDC, La Renon, Cadila, Corona & Indoco* have shown improvement in MS for Jan’24 as compared to Dec’23
• Ajanta has maintained MS in the month of Jan’24
• JB Pharma* & Himalaya have reflected dip in MS for Jan’24 as compared to Dec’23

IQVIA TSA & SSA Dataset Jan’24 7

 Top Companies #21-30
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

90 PFIZER* 206 -5 88
PFIZER* 271 -3
102 JB PHARMA* 186 15 106
JB PHARMA* 209 11
9 101 ERIS* 171 10 102
ERIS* 197
3 96 FDC 169 4 96
FDC 184
Month

Month
11 102 AJANTA 124 12 103
AJANTA 140
10 102 HIMALAYA 118 9 101
HIMALAYA 133
18 110 CADILA 104 7 99
LA RENON 126
4 96 LA RENON 101 17 108
CADILA 125
22 113 INDOCO* 99 4 96
CORONA 109
3 95 BLUE CROSS 95 3 95
INDOCO* 109

ALEMBIC 3,196 99 PFIZER* 2,532 1 92

9
JB PHARMA* 2,427 103 JB PHARMA* 2,135 14 104
13
ERIS* 2,253 98 FDC 2,047 11 101
8
FDC 2,228 101 ERIS* 1,957 9 99
11
MAT

97 6 96

MAT
HIMALAYA 1,729 HIMALAYA 1,539
7
AJANTA 1,616 101 AJANTA 1,431 11 101
11
CADILA 1,586 98 CADILA 1,309 9 99
8
LA RENON 1,451 111 FRANCO 1,286 1 92
22
FRANCO 1,385 91 LA RENON 1,174 21 110
0
INDOCO* 1,292 95 INDOCO* 1,167 4 95
5

• TSA : Corona has posted highest growth for the month followed by La Renon, while on MAT level, La Renon is the fastest growing company

• SSA : La Renon has posted highest growth followed by JB Pharma* for the month, while on MAT, La Renon is the fastest growing company

IQVIA TSA & SSA Dataset Jan'24

8
 Top Companies #31-40 Market Share Trend
0.75 Val Jan’24 MS Jan’24
HETERO* 107 0.60
0.70
BLUE CROSS 103 0.57

(FRANCO) 97 0.54
0.65
SYSTOPIC 92 0.51

P&G HLTH 87 0.49

0.60
FOURRTS 80 0.45

MEDLEY 78 0.44
0.55
WIN MEDICARE 75 0.42

0.50 H&H 74 0.41

BHARAT SERUM 72 0.40

0.45

0.40

0.35
Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23 Nov’23 Dec’23 Jan’24

• Hetero*, Blue Cross, Systopic, Fourrts, Medley & Bharat Serum have shown improvement in MS for Jan’24 as compared to Dec’23
• P&G, Win Medicare & H&H have maintained MS in the month of Jan’24
• Franco reflected dip in MS for Jan’24 as compared to Dec’23

IQVIA TSA & SSA Dataset Jan’24 9

 Top Companies #31-40
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

HETERO* 107 17 108 CORONA 92 24 115

BLUE CROSS 103 1 94 FRANCO 89 -13 81
FRANCO 97 -12 81 HETERO* 85 15 107
SYSTOPIC 92 14 105 SYSTOPIC 82 15 106
Month

Month
P&G HLTH 87 -5 88 P&G HLTH 80 -4 89
FOURRTS 80 13 104 MEDLEY 73 7 99
MEDLEY 78 6 98 FOURRTS 69 14 105
WIN MEDICARE 75 1 93 WIN MEDICARE 66 1 93
H&H 74 2 94 H&H 64 2 94
BHARAT SERUM 72 7 99 APEX 56 2 94

CORONA 1,269 17 107 BLUE CROSS 1,147 8 99

BLUE CROSS 1,254 8 98 CORONA 1,070 18 107
HETERO* 1,249 23 112 P&G HLTH 1,060 1 92
P&G HLTH 1,165 2 92 HETERO* 997 22 111
MAT

101 11 101

MAT
SYSTOPIC 1,081 11 SYSTOPIC 965
MEDLEY 1,022 5 95 MEDLEY 960 5 96
WIN MEDICARE 941 8 98 WIN MEDICARE 822 9 100
FOURRTS 905 14 104 FOURRTS 779 13 103
H&H 903 4 94 H&H 778 2 93
BHARAT SERUM 840 4 94 APEX 730 5 96

• TSA: Hetero* showed the highest growth at month level, while for MAT, Hetero* has posted highest growth followed by Corona
• SSA: Corona showed the highest growth at month level, while for MAT, Hetero* has posted highest growth followed by Corona

IQVIA TSA & SSA Dataset Jan'24

10
 Top Companies #41-50 Market Share Trend
0.42
0.41
0.40 Val Jan’24 MS Jan’24
0.39 (JANSSEN) 65 0.37
0.38
0.37
MEYER 65 0.36

0.36 (APEX) 64 0.35

0.35 (ASTRA) 63 0.35
0.34
0.33 WALLACE 61 0.34
0.32 MSD* 59 0.33
0.31
CENTAUR 57 0.32
0.30
0.29 (SAMARTH) 56 0.31
0.28 RAPTAKOS 56 0.31
0.27
0.26
(BOEHRINGER) 53 0.30

0.25
0.24
0.23
0.22
0.21
Jan’23 Feb’23 Mar’23 Apr’22 May’22 Jun’22 Jul’22 Aug’23 Sep’23 Oct’23 Nov’23 Dec’23 Jan’24

• Wallace has shown improvement in MS for Jan’24 as compared to Dec’23

• Meyer, MSD* Centaur and Raptakos have maintained MS in the month of Jan’24
• Janssen, Apex, Astra, Samarth & Boehringer reflected dip in MS for Jan’24 as compared to Dec'23

IQVIA TSA & SSA Dataset Jan’24 11

 Top Companies #41-50
TSA SSA

Value (Rs. Crs) % Gwth EI Value (Rs. Crs) % Gwth EI

MEYER 55 2 94
JANSSEN 65 6 99
WALLACE 55 1 93
MEYER 65 3 95
CENTAUR 53 5 97
APEX 64 2 94
BHARAT SERUM 51 9 101
ASTRA 63 18 110
Month

Month
RAPTAKOS 49 4 96
WALLACE 61 0 93
BOEHRINGER 45 0 92
MSD* 59 -2 91
JANSSEN 44 4 97
CENTAUR 57 4 96
PHARMED 44 7 99
SAMARTH 56 9 101
MSD* 43 2 94
RAPTAKOS 56 3 96
NUTRICIA 40 16 108
BOEHRINGER 53 -4 89

JANSSEN 827 3 94 WALLACE 725 8 98

MEYER 826 9 99 MEYER 705 9 99
APEX 825 5 95 RAPTAKOS 644 5 95
WALLACE 810 8 98 BHARAT SERUM 600 3 93
MAT

-3

MAT
RAPTAKOS 739 6 96 BOEHRINGER 595 88
MSD* 727 -2 89 CENTAUR 572 7 98
BOEHRINGER 703 -5 87 JANSSEN 556 -2 89
SAMARTH 698 21 110 PHARMED 543 11 101
ASTRA 694 21 110 MSD* 522 -4 87
PHARMED 628 10 100 WOCKHARDT* 471 7 97

• TSA: Astrazeneca showed the highest growth at month level, while for MAT, Samarth is the fastest growing company followed by Astrazeneca

• SSA: Nutricia showed the highest growth at month level, while for MAT, Pharmed is the fastest growing company followed by Meyer

IQVIA TSA & SSA Dataset Jan'24

12
 Top 40 Brands
TSA

Value % Gwth Value

%MS % Gwth % MS
(Rs. Crs) (Rs. Crs)

20 0.47 0.22
FORACORT 83 MONOCEF 39 3
1 0.40 0.22
MIXTARD 72 ROSUVAS 39 22
8 0.39 0.20
GLYCOMET-GP 70 SHELCAL 36 5
Top 1-10

Top 21-30
-1 0.38 0.20
AUGMENTIN 69 MOXIKIND-CV 36 9
5 0.29 0.19
ELECTRAL 53 LEVIPIL 35 12
-10 0.29 0.19
CLAVAM 52 PREVENAR-13 35 26
10 0.28 0.19
DUOLIN 51 ECOSPRIN-AV 35 13
18 0.28 0.19
BUDECORT 51 TELMA-H 35 31
5 0.28 0.19
THYRONORM 50 CILACAR 34 25
6 0.27 0.19
PAN 48 DUPHASTON 34 13
0.26 33 0.19
UDILIV 47 33 ACILOC 12
0.26 ULTRACET 33 10 0.18
LANTUS 47 -5
0.26 0.18
Top 11-20

MANFORCE 47 12 DOLO 32 -8

Top 31-40
0.26 TELMA-AM 32 32 0.18
RYZODEG 46 15
LIV-52 45 32 0.25 RANTAC 30 9 0.17
BETADINE 45 -2 0.25 RYBELSUS 30 109 0.17
PAN-D 44 14 0.25 NOVOMIX 30 -12 0.17
TELMA 43 27 0.24 GLUCONORM-G 29 17 0.16
ZERODOL-SP 41 18 0.23 SEROFLO 29 15 0.16
AZITHRAL 39 -3 0.22 MONTAIR-LC 29 2 0.16

• Foracort is the topmost brand with 83 Crs of sales & MS of ~0.47% for the month

• Amongst the top 10 brands, Foracort has shown highest growth followed by Budecort for the month

IQVIA TSA & SSA Dataset Jan'24

13
 Star Brands of the month
TSA
Movers & Shakers TSA: Products

Among the Top 25 products as per Jan'24 Month (in comparison to Dec'23 Month)

• Foracort is No 1 position brand at month level with a growth of 20%

• Amongst the top 10 Brands, highest growth is observed by Foracort
• Mixtard, Lantus, Betadine, Moxikind-CV, Levipil gained 1 rank to secure 2nd, 12th, 16th, 24th & 25th position with a growth of 1%, -5%,
-2%, 9%, 12% respectively
• Clavam, Ryzodeg, Telma gained 2 ranks to secure 6th, 14th, 18th position with a growth of -10%,15%, 27% respectively
• Electral gained 128 ranks to reach 5th position with a growth of 5%

IQVIA TSA & SSA Dataset Jan'24

14
 Highlight
TSA SSA
Movers & Shakers TSA: Companies Movers & Shakers SSA: Companies

In the month of Jan’24 (in comparison to Dec'23), amongst
the Top 25 companies
• Sun* has maintained its top position in the IPM with a market
share of 8%
• FDC & Ajanta improved by 1 rank each to reach 24th & 25th
positions respectively
• USV improved by 2 ranks to reach 15th position
In the month of Jan’24 (in comparison to Dec'23), amongst
the Top 25 companies
• Sun* has maintained its top position in the IPM with a market
share of 8%
• Emcure*, FDC & Ajanta improved by 1 rank each to reach 16th,
24th & 25th positions respectively

As per MAT Jan’24 (in comparison to MAT Dec'23), amongst
the Top 25 companies
• Sun* has maintained its top position in the IPM with a market
share of 8%
• JB Pharma* improved by 2 ranks to reach 22nd position
As per MAT Jan’24 (in comparison to MAT Dec’23), amongst
the Top 25 companies
• Sun* has maintained its top position in the IPM with a market
share of 8%
• JB Pharma* improved by 1 rank to reach 22nd position

IQVIA TSA & SSA Dataset Jan’24

15
 Indian / MNC trends % Growth Over Same Month Last Year Indian MNC
30
26
25
21
20 17
15
Month Growth

15 18 14
13
11
10 9
8
9 7 7 8
6 6 6 7
5
5 4
2 4
3
3
0
FEB’23 MAR’23 APR’22 MAY’22 JUN’22 JUL’22 AUG’23 SEP’23 OCT’23 NOV’23 DEC’23 JAN’24

Value (Rs. Crs)

Indian MNC

16,691 17,158 17,953 17,234 16,622 17,863 18,719 19,208 19,003 18,016 18,073 17,937
Share in IPM

13,872 14,159 14,883 14,288 13,800 14,856 15,603 16,025 15,844 14,961 15,028 14,932

2,819 2,998 3,070 2,946 2,822 3,007 3,116 3,182 3,159 3,056 3,045 3,006

FEB’23 MAR’23 APR’22 MAY’22 JUN’22 JUL’22 AUG’23 SEP’23 OCT’23 NOV’23 DEC’23 JAN’24

• Indian companies registered growth of 8% whereas MNC’s registered growth of 7% for the month

IQVIA TSA & SSA Dataset Jan'24 16

 Acute / Chronic Trends
ACUTE CHRONIC
30 27
25 22
20
20 18
Growth (%)

15 15
15 13 12
11 11
9 8 10 9 9 8
10 9 7
3 5 4
5 3 6
2
0
FEB’23 MAR’23 APR’22 MAY’22 JUN’22 JUL’22 AUG’23 SEP’23 OCT’23 NOV’23 DEC’23 JAN’24

Gwth %
6.0% -12.2% 0.1% 3.0% 14.4%
Top 5 TC 4s

284
247
Value (Rs 222 205 183
Crs)

GLIMEPIRIDE+METFORM. COUGH PREP. ETHICALS AMOXY. & CLAV. SOLIDS INTER.-ACTING+FAST ACTING FOOD SUPPLEMENTS

Value (Rs. Crs)

Top 3 Cos. in TC4

USV 70 GLENMARK 45 GSK* 48 ABBOTT* 149 APEX 26

LUPIN 32 DRL 28 ALKEM* 35 LUPIN 27 ALKEM* 25

SUN* 27 MANKIND 22 MANKIND 33 CIPLA 11 SUN* 19

• Acute has shown growth of 6% whereas Chronic has shown growth of 11% for the month

IQVIA TSA & SSA Dataset Aug’21

IQVIA TSA & SSA Dataset Jan'24 17
 Top Therapy Trends
TSA

Value_Jan'24 (Rs. Crs) % Gwth SPLY Value_Jan'24 (Rs. Crs) % Gwth SPLY

C10A04 ROSUVASTATIN 122 13 J01C0G AMOXY. & CLAV. SOLIDS 222 0

C02C04 TELMISARTAN 108 12 J01N01 MEROPENEM 124 22

17 J01C0H AMOXY. & CLAV. LIQUIDS 107 -3

Anti-Infectives
C02F06 AMLODIPINE+TELMISARTAN 101
C02G0H TELMISARTAN + HCT 82 16 J01D0C CEFTRIAXONE INJECTABLS 103 3
Cardiac

C10A03 ATORVASTATIN 75 -9 J01F04 AZITHROMYCIN ORAL SOLIDS 93 -3

B01A0E ENOXAPARIN 69 20 J01D0L CEFIXIME ORAL SOL. 73 1

C01D0B CILNIDIPINE 64 19 J01K05 PIPERACILLIN+TAZOBACTAM 71 11

C02F02 ATENOLOL+AMLODIPINE 60 10 J01D0Z CEFTRIAXONE+SULBACTAM 70 12

C02F0I METOPROLOL+TELMISARTAN 59 14 J01D0I CEFUROXIME ORAL SOLIDS 65 -9

C01E03 METOPROLOL 59 2 J01D0V CEFPODOXIME SOLIDS 64 2

A02B0Q PANTOPR.+ DOMPERID. 131 7 A10B0Q GLIMEPIRIDE+METFORM. 284 6

A02B0R RABEPRA.+ DOMPERID. 100 6 A10C03 INTER.-ACTING+FAST ACTING 205 3
A02B0A PANTOPRAZOLE SOLIDS 98 6 A10B0B GLIMEPIRIDE+METFOR+VOGLIB 109 11
4

Anti Diabetic
A07L01 ORAL ELECTROLYTES 83 A10C05 LONG ACTING 93 4
A02B0S ESOMEPR.+ DOMPERID. 73 36 A10B0D METFORMIN + VILDAGLIPTIN 75 1
GI

A07K09 OTHERS 64 14 A10C01 FAST ACTING 75 9

A02B01 RANITIDINE ORAL SOLIDS 58 9 A10B07 METFORMIN + SITAGLIPTIN 67 22
A06A07 MILK OF MAG AND COMB. 55 23 A10B0W PIOGLITAZ.+METFORM.+GLIM. 66 10
A02A05 ANTACID+ANTIFLATU.LIQ 55 27 A10B12 DAPAGLIFLOZIN 49 9
A06A0A LACTULOSE 51 10 A10B0M GLICLAZIDE + METFORMIN 45 11

• In Cardiac, Enoxaparin posted highest growth of 20%

• In AI, Meropenem posted highest growth of 22%
• In GI, Esomep+Domperidone posted highest growth of 36%
• In Anti diabetic, Glimepride+Metformin registered highest sales of 284 Cr with a growth of 6%

IQVIA TSA & SSA Dataset Jan'24 18

 Top Therapy Trends
TSA

Value_Jan'24 (Rs. Crs) % Gwth SPLY Value_Jan'24 (Rs. Crs) % Gwth SPLY

R05B01 COUGH PREP. ETHICALS 247 -12 M02A01 NSAIDS 79 5

R03C0R FORMOTERAL+BUDESONIDE 137 18 M05C02 CALCITRIOL COMB. 71 3
R03B01 LEVOCETIRIZ.+MONTELU SOLD 117 1 M01A0G PARACE.+ACECLOF.+SERRAPE. 69 15
Respiratory

R05B05 LEVOSALBUTAMOL & COMB. 106 0 N02B05 PARACETAMOL ORAL SOLIDS 65 -4

Pain
R05A02 COLD PREP. LIQUIDS 82 -10 M01A0U ACECLOFENAC + PARACETAMOL 47 16
R05B07 CHLORPHNMN+DEXTROMETHRPHN 76 -2 N02B0K PARACETAMOL + TRAMADOL 44 9
R03C02 BUDESONIDE 61 13 M05B0C COLLAGEN COMB 44 10
R03C0S IPRATROPIUM + LEVOSALBU. 60 8 N02B06 PARACETAMOL ORAL LIQUIDS 38 -10
R05A01 COLD PREP. SOLIDS 56 8 N02B07 PARACETAMOL INJECTIONS 37 10
R03C0P SALMETEROL+FLUTICASONE 39 9 M01A03 DICLOFENAC INJECTABLES 33 7

V06E01 FOOD SUPPLEMENTS 183 14 D02A01 EMOLLIENTS,PROTECTIVES 156 10

V06C01 INFANT FORMULAS 104 22 D01C03 ITRACONAZOLE 73 4
A12A04 CALCIUM + COLECALCI. SOLI. 101 8 D11A09 OTH.DERMATOLOGICAL PREP. 61 9
A11F02 MECOBALAMIN COMB. 94 5 D02B01 SUNSCREENS 40 23

Derma
A11C02 PLAIN VIT.D 82 12 D06A08 MUPIROCIN 34 -7
VMN

A11A04 OTH. MULTIVIT.-MIN. SOLIDS 65 6 D16A0D OTH HAIR CARE PREPS. 33 18

A12A01 CALCIUM ORAL SOLIDS 48 12 D01A02 LULICONAZOLE 30 2
A11F05 MECOBALAM.+COLECALI. COMB 37 9 D02C07 HYDROQU.+TRETI.+MOMETA. 30 -5
V06E05 ADULT WELLNESS 37 -2 D07D0C CLOBET+MICONAZOL+NEOMYCIN 27 -14
A15A01 APPETITE STIMULANTS 36 -5 D02E01 MINOXIDIL 24 -2

• In Respiratory therapy, Formoteral+Budesonide posted highest growth of 18%

• In Pain market, Paracetamol oral solids, liquids & inj contributed ~ 140 Cr of sales with -4%, -10% and 10% growth respectively
• In VMN, Food supplements is the top contributing subgroup with 183 Cr of sales and posted a growth of 14%
• Emollients & protectives registered highest sales of 156 Cr in derma market with 10% growth while the highest growth of 23% is observed in Sunscreens

IQVIA TSA & SSA Dataset Jan'24 19

 Top Therapy Trends
TSA

Value_Jan'24 (Rs. Crs) % Gwth SPLY Value_Jan'24 (Rs. Crs) % Gwth SPLY

N03A0T LEVETIRACETAM 94 8 B03A01 CONV.IRON SOLIDS 105 3

N06C02 ESCITALOPRAM+CLONAZEPAM 45 11 G03D04 DYDROGESTERONE 103 18
N03A0V GABAPENTIN + NORTRIPTYLIN 42 22 B03A02 CONV.IRON LIQUID 77 6
Neuro/CNS

Gynaec
N07C01 BETAHISTINE 36 6 G03D03 PROGESTERONE 77 6
N03A0J OXCARBAZEPINE 29 12 B03A03 CONV.IRON INJ. 56 9
N07A01 PREGABALIN 26 8 G03K02 MIFEPRISTONE+MISOPROSTOL 46 7
N07A02 PREGABALIN+MECOBALAMIN 25 3 G03G06 HUMAN MENOPAUSAL GONADOTROP. 40 34
N03A04 SODIUM VALPROATE ORAL SOLIDS 24 -8 G02C01 OTHER GYNAECO.PREP. 32 4
N03A0I NORTRIPTYLINE+PREGABALIN 24 6 G03G05 HUMAN CHORIONIC GONADOTROP. 28 -2
N03A10 BRIVARACETAM 22 38 G03D02 NORETHISTERONE 24 8

V03D04 SILDENAFIL 54 7 S01J03 METHYL CELLULOSE/CMC 40 -2

G03J0A DUTASTERIDE + TAMSULOSIN 37 14 S02A01 OTOLOGICALS 21 12
G03J0G DUTASTERIDE + SILODOSIN 35 25 S01A0A MOXIFLOXACIN 19 -5
G04B09 OTH. UROLOGICAL PREP. 28 10 S01J07 HYALURONIC ACID 16 19

Ophthal
Urology

G03J03 TAMSULOSIN 25 11 S01J0A MACROGOL+PROPYL.GLY&COMB 15 16

V03D05 TADALAFIL 21 26 S01H06 NEPAFENAC 14 10
G03J0E SILODOSIN 21 15 S01P04 ANTI-OXIDANTS-OPHTHAL 12 -1
G04B0D ALPHA KETOANALOGUE 17 19 S01G0A BRIMONIDINE + TIMOLOL 12 10
G04B01 URINARY ALKALISERS 16 9 S01J04 HPMC 11 1
G04B02 FLAVOXATE 14 24 S01P07 RANIBIZUMAB 8 59

• In Neuro therapy, Levetiracetam is the top contributing subgroup with 94 Cr of sales with a growth of 8%
• In Gynaec therapy, Conv iron solids, liquids and inj. together have contributed to ~238 Cr of sales
• In Urology therapy, Tadalafil posted highest growth of 26%
• Methyl Cellulose registered highest sales of 40 Cr in ophthal therapy with -2% degrowth

IQVIA TSA & SSA Dataset Jan'24 20

Key changes
PTR Changes (Top 50 brands) New Introduction

➢ Total number of SKUs with PTR changes in Jan’24 are 1986. ➢ 622 new packs were Introduced in Jan’24
➢ Among the top 50 brands of the industry, PTR changes reflected in SKUs
of the following brands : Foracort, Augmentin, Thyronorm, Liv-52, Udiliv,
Azithral, Budecort, Rantac, Pantop, Volini, Gemer, Pantop-D &
Gluconorm-G

New Lab & Corporate Brand Transfer

➢ Loreal India, Mother Sparsh Baby & Wonset Helathcare have been ➢ 14 brand transfers registered in Jan’24
introduced in Jan’24 dataset

IQVIA TSA & SSA Dataset Jan’24 21

THANK YOU